EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains

Andres Ceballos-Garzon iD, Julien Lebrat, Marion Holzapfel, Diego F Josa, Jeremy Welsch, Derry Mercer

Antimicrobial Agents and Chemotherapy · 04.06.2025 · 69 (6)

DOI: 10.1128/aac.00137-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.06.2025. Verfasst von Andres Ceballos-Garzon und 5 weiteren Autor:innen. Beteiligte Einrichtung: BIOASTER Research Institute, Lyon, France. Hauptthemen laut MEDLINE: Biofilms, Antifungal Agents, Amphotericin B, Candida. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BIOASTER.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the Calgary biofilm device. Mature-phase biofilms of C. albicans , C. auris (clades I, II, III, IV ), and C. parapsilosis were exposed to a range of drug concentrations (0.12–128 µg/mL). Minimum Inhibitory Concentration (MIC) values for planktonic cells were ≤2 µg/mL for all strains; however, biofilm-associated MICs, minimum biocidal concentration (MBC), minimum biofilm eradication (MBEC), and minimum biofilm damaging concentration (MBDC) were significantly higher (2–4,119 times). Geometric mean (GM) of MBEC values indicated that MNGX had the highest antifungal activity within Candida species, with a GM-MBEC of 5.9 µg/mL. Despite its overall potency, MNGX was less effective against C. auris biofilms from clade IV strains, where IBF showed superior activity. While not the most potent agent overall, AMB induced the smallest fold-change increases (2- to 32-fold) in biofilm-associated states data compared to planktonic MICs. Conversely, CAS exhibited the lowest activity against Candida spp. biofilms. The eradication of C. auris and C. parapsilosis biofilms required substantially higher concentrations than C. albicans , with some agents, such as RZF and CAS, necessitating up to 42-fold increases in dosage. In conclusion, our in vitro model highlights the antibiofilm activity of novel antifungals against major Candida species, revealing significant differences in efficacy among species. MNGX demonstrated the highest activity, underscoring its potential as a promising candidate for the treatment of biofilm-related infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsAntifungal AgentsAmphotericin BCandidaEchinocandinsMicrobial Sensitivity TestsCaspofunginCandida albicansHumansCandida parapsilosisCandida aurisCandidiasisGlycosidesTriterpenes

Stichwörter der Autor:innen

Calgary biofilm deviceCandida biofilmsantibiofilm activitynovel antifungals

Substanzen

Antifungal AgentsCaspofunginAmphotericin BRezafunginibrexafungerpEchinocandinsGlycosidesTriterpenes

Autor:innen und Institutionen

  • BIOASTER Research Institute, Lyon, France.
  • Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia.
  • Department of Infectious Diseases, Universidad de La Sabana, Bogota, Colombia.

ORCID-Profile: Andres Ceballos-Garzon

Förderung

  • BIOASTER

Zitieren

APA

Ceballos-Garzon, A., Lebrat, J., Holzapfel, M., Josa, D. F., Welsch, J., & Mercer, D. (2025). Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. Antimicrobial Agents and Chemotherapy, 69(6). https://doi.org/10.1128/aac.00137-25

Vancouver

Ceballos-Garzon A, Lebrat J, Holzapfel M, Josa DF, Welsch J, Mercer D. Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. Antimicrobial Agents and Chemotherapy. 2025;69(6). doi:10.1128/aac.00137-25

BibTeX
@article{CeballosGarzon2025,
  author = {Ceballos-Garzon, Andres and Lebrat, Julien and Holzapfel, Marion and Josa, Diego F and Welsch, Jeremy and Mercer, Derry},
  title = {Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {6},
  doi = {10.1128/aac.00137-25}
}
Kostenlos starten →